Cargando…

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer

SIMPLE SUMMARY: A tremendous effort and rapid development of the prostate-specific membrane antigen (PSMA)-targeting radio ligands for radionuclide therapy has resulted in encouraging response rates for advanced prostate cancer. Different radionuclides have been utilized or suggested as suitable can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhardt, Peter, Svensson, Johanna, Hemmingsson, Jens, van der Meulen, Nicholas P., Zeevaart, Jan Rijn, Konijnenberg, Mark W., Müller, Cristina, Kindblom, Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122331/ https://www.ncbi.nlm.nih.gov/pubmed/33921956 http://dx.doi.org/10.3390/cancers13092011

Ejemplares similares

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
por: Hemmingsson, Jens, et al.
Publicado: (2022)

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
por: Juget, Frédéric, et al.
Publicado: (2022)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

A simple and automated method for (161)Tb purification and ICP-MS analysis of (161)Tb
por: McNeil, Scott W., et al.
Publicado: (2022)

Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
por: Borgna, Francesca, et al.
Publicado: (2021)

Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases
por: Falzone, Nadia, et al.
Publicado: (2018)

Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
por: Champion, Christophe, et al.
Publicado: (2016)

Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide
por: Idrissou, Malick Bio, et al.
Publicado: (2021)

Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
por: Tamborino, Giulia, et al.
Publicado: (2022)

Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
por: Loke, Kelvin S. H., et al.
Publicado: (2011)

Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
por: Wendt, Richard E., et al.
Publicado: (2022)

A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity
por: Svensson, Johanna, et al.
Publicado: (2016)

Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [(177)Lu]Lu-DOTATATE Treatment
por: Hemmingsson, Jens, et al.
Publicado: (2023)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
por: Kgatle, Mankgopo M., et al.
Publicado: (2021)

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with (68)Ga, (44)Sc, (177)Lu and (161)Tb
por: Talip, Zeynep, et al.
Publicado: (2020)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases
por: Alcocer-Ávila, Mario E., et al.
Publicado: (2020)

Optimisation of clinical SPECT imaging with 155Tb for theragnostic radionuclide therapy
por: Cocolios, Thomas Elias, et al.
Publicado: (2016)

Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities
por: Hemmingsson, Jens, et al.
Publicado: (2018)

Preclinical Evaluation of [(155/161)Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours
por: Wharton, Luke, et al.
Publicado: (2023)

A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
por: Holzwarth, Uwe, et al.
Publicado: (2018)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Evaluation of Dosimetric Parameters for Tumor Therapy with (177)Lu and (90)Y Radionuclides in Gate Monte Carlo Code
por: Peer-Firozjaei, Milad, et al.
Publicado: (2021)

LEMMA-TB: an experiment to measure the production of a low emittance muon beam
por: Zanetti, Marco, et al.
Publicado: (2020)

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods
por: UYGUR, EMRE, et al.
Publicado: (2023)

New Radionuclides and Technological Advances in SPECT and PET Scanners
por: van der Meulen, Nicholas P., et al.
Publicado: (2021)

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain
por: Manafi-Farid, Reyhaneh, et al.
Publicado: (2020)

Dosimetric impact of range uncertainty in passive scattering proton therapy
por: Liu, Ruirui, et al.
Publicado: (2021)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Room temperature solid-state quantum emitters in the telecom range
por: Zhou, Yu, et al.
Publicado: (2018)

Hybridization of short-range and long-range charge transfer excited states in multiple resonance emitter
por: Lee, Ha Lim, et al.
Publicado: (2023)

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
por: Cunningham, S. H., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_v6vo0dailk95gd9aupout3isg1